Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta Therapeutics (SRPT) shares are under significant pressure following the delayed disclosure of a patient death in a clinical trial and the company's unprecedented refusal to comply with an FDA request to halt shipments of its Duchenne muscular dystrophy drug, Elevidys. This defiance, coupled with two prior patient fatalities linked to Elevidys, has severely eroded investor confidence and prompted analyst downgrades, raising critical questions about management transparency, the company's gene therapy platform, and the potential for regulatory action. While some analysts anticipate Elevidys will remain available for ambulatory patients, the ongoing standoff creates substantial uncertainty regarding future sales and Sarepta's operational stability, particularly given its 88% year-to-date stock decline.

Analysis

Sarepta Therapeutics (SRPT) is confronting a severe crisis driven by a collapse in management credibility and a direct standoff with the FDA, precipitating a 35% stock decline on Friday and an 88% fall year-to-date. The turmoil stems from two core events: the delayed disclosure of a patient death in a clinical trial, which executives deemed not 'material' for an earnings call, and the company's unprecedented refusal of an FDA request to halt shipments of its approved drug, Elevidys. This defiance has put the company in what analysts call 'unprecedented times' and prompted a downgrade from Leerink Partners, which cited a loss of confidence in the management team. While weekend discussions with analysts, such as JPMorgan's Anupam Rama, have introduced a nuanced view that there is upside if Elevidys remains on the market for ambulatory patients, the situation remains highly volatile. The central risk is now the outcome of the FDA confrontation, which JPMorgan's analyst noted would be 'thesis changing.' Furthermore, with this being the third patient death in a year, Jefferies' analyst highlights concerns that the entire gene therapy platform's safety profile is now in question, potentially leading to long-term 'stock exhaustion.'

Key Decisions for Investors

• Monitor the regulatory standoff with the FDA over Elevidys, as the outcome represents the most significant near-term catalyst and a pivotal, binary risk to the company's fundamental valuation.
• Critically re-evaluate management's credibility and governance, as the delayed disclosure of material safety information and public defiance of the FDA have created a significant trust deficit that could impact future regulatory interactions.
• Assess Sarepta's financial viability under a stress scenario where Elevidys sales are halted or significantly impacted, given management's own admission that such an event would necessitate further cost-cutting to stay afloat.